Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.

Svensson J, Lönn L, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Boseaus I, Sjöström L, Bengtsson BA

The Journal of clinical endocrinology and metabolism1 Feb 1998Cited by 98 (Europe PMC)

PMID9467542DOI10.1210/jcem.83.2.4539PepBankPUB-09467542

Source link PubMedAsk about this study

Jump to 23 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study23

23 results from studies that gave the peptide. 23 results from people.

01HumanRandomized controlled trialEfficacy outcome
In obese males, MK‑677 increased IGF-I compared with placebo.
In plain wordsIn obese males, MK‑677 increased IGF-I compared with placebo.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseIGF-I
Study
n = 24
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
25 mg daily · oral · 8 weeksAs given in this study (human).
Measurements
IGF-I increase
≈ 40%
MK-677 vs placebo, 8 weeks
P value for serum IGF-I increase
< 0.001 unitless
MK-677 vs. placebo
Source sentences
Summary
Serum insulin-like growth factor I (IGF-I) increased approximately 40% with MK-677 treatment (P < 0.001 vs. placebo).
2 context sentences(design, population, supporting numbers)
Summary · context
The study was randomized, double blind, parallel, and placebo controlled.
Summary · context
Twenty-four obese males, aged 18-50 yr, with body mass indexes greater than 30 kg/m2 and waist/hip ratios greater than 0.95, were treated with MK-677 25 mg (n = 12) or placebo (n = 12) daily for 8 weeks.
Report a problemFND-0946754201
02HumanRandomized controlled trialEfficacy outcome
In obese males, MK‑677 increased IGF-binding protein-3 compared with placebo.
In plain wordsIn obese males, MK‑677 increased IGF-binding protein-3 compared with placebo.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseIGF-binding protein-3
Study
n = 24
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
25 mg daily · oral · 8 weeksAs given in this study (human).
Measurements
P value for serum IGF-binding protein-3 increase
≤ 0.001 unitless
MK-677 vs. placebo
Source sentences
Summary
Serum IGF-binding protein-3 was also significantly increased (P < or = 0.001 vs. placebo).
2 context sentences(design, population, supporting numbers)
Summary · context
The study was randomized, double blind, parallel, and placebo controlled.
Summary · context
Twenty-four obese males, aged 18-50 yr, with body mass indexes greater than 30 kg/m2 and waist/hip ratios greater than 0.95, were treated with MK-677 25 mg (n = 12) or placebo (n = 12) daily for 8 weeks.
Report a problemFND-0946754202
03HumanRandomized controlled trialEfficacy outcome
In obese males, the initial MK‑677 dose significantly increased peak GH.
In plain wordsIn obese males, the initial MK‑677 dose significantly increased peak growth hormone.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseInitial GH peak
Study
n = 24
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
25 mg daily · oral · initial doseAs given in this study (human).
Source sentences
Summary
GH and PRL (peak and area under the curve values) were significantly increased after the initial dose of MK-677.
2 context sentences(design, population, supporting numbers)
Summary · context
The study was randomized, double blind, parallel, and placebo controlled.
Summary · context
Twenty-four obese males, aged 18-50 yr, with body mass indexes greater than 30 kg/m2 and waist/hip ratios greater than 0.95, were treated with MK-677 25 mg (n = 12) or placebo (n = 12) daily for 8 weeks.
Report a problemFND-0946754203
04HumanRandomized controlled trialEfficacy outcome
In obese males, the initial MK‑677 dose significantly increased GH area under the curve.
In plain wordsIn obese males, the initial MK‑677 dose significantly increased growth hormone area under the curve.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseInitial GH area under the curve
Study
n = 24
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
25 mg daily · oral · initial doseAs given in this study (human).
Source sentences
Summary
GH and PRL (peak and area under the curve values) were significantly increased after the initial dose of MK-677.
2 context sentences(design, population, supporting numbers)
Summary · context
The study was randomized, double blind, parallel, and placebo controlled.
Summary · context
Twenty-four obese males, aged 18-50 yr, with body mass indexes greater than 30 kg/m2 and waist/hip ratios greater than 0.95, were treated with MK-677 25 mg (n = 12) or placebo (n = 12) daily for 8 weeks.
Report a problemFND-0946754204
05HumanRandomized controlled trialEfficacy outcome
In obese males, the initial MK‑677 dose significantly increased peak PRL.
In plain wordsIn obese males, the initial MK‑677 dose significantly increased peak prolactin.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseInitial PRL peak
Study
n = 24
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
25 mg daily · oral · initial doseAs given in this study (human).
Source sentences
Summary
GH and PRL (peak and area under the curve values) were significantly increased after the initial dose of MK-677.
2 context sentences(design, population, supporting numbers)
Summary · context
The study was randomized, double blind, parallel, and placebo controlled.
Summary · context
Twenty-four obese males, aged 18-50 yr, with body mass indexes greater than 30 kg/m2 and waist/hip ratios greater than 0.95, were treated with MK-677 25 mg (n = 12) or placebo (n = 12) daily for 8 weeks.
Report a problemFND-0946754205
06HumanRandomized controlled trialEfficacy outcome
In obese males, the initial MK‑677 dose significantly increased PRL area under the curve.
In plain wordsIn obese males, the initial MK‑677 dose significantly increased prolactin area under the curve.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseInitial PRL area under the curve
Study
n = 24
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
25 mg daily · oral · initial doseAs given in this study (human).
Source sentences
Summary
GH and PRL (peak and area under the curve values) were significantly increased after the initial dose of MK-677.
2 context sentences(design, population, supporting numbers)
Summary · context
The study was randomized, double blind, parallel, and placebo controlled.
Summary · context
Twenty-four obese males, aged 18-50 yr, with body mass indexes greater than 30 kg/m2 and waist/hip ratios greater than 0.95, were treated with MK-677 25 mg (n = 12) or placebo (n = 12) daily for 8 weeks.
Report a problemFND-0946754206
07HumanRandomized controlled trialEfficacy outcome
In obese males, increased peak GH persisted during repeated MK‑677 treatment.
In plain wordsIn obese males, increased peak growth hormone persisted during repeated MK‑677 treatment.
Peptide
MK-677 (ibutamoren)
Outcome
IncreasePersistent GH peak
Study
n = 24
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
25 mg daily · oral · 8 weeksAs given in this study (human).
Source sentences
Summary
Significant increases, with the exception of peak PRL, persisted at 2 and 8 weeks of treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
GH and PRL (peak and area under the curve values) were significantly increased after the initial dose of MK-677.
Summary · context
The study was randomized, double blind, parallel, and placebo controlled.
Summary · context
Twenty-four obese males, aged 18-50 yr, with body mass indexes greater than 30 kg/m2 and waist/hip ratios greater than 0.95, were treated with MK-677 25 mg (n = 12) or placebo (n = 12) daily for 8 weeks.
Report a problemFND-0946754207
08HumanRandomized controlled trialEfficacy outcome
In obese males, increased GH area under the curve persisted during repeated MK‑677 treatment.
In plain wordsIn obese males, increased growth hormone area under the curve persisted during repeated MK‑677 treatment.
Peptide
MK-677 (ibutamoren)
Outcome
IncreasePersistent GH area under the curve
Study
n = 24
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
25 mg daily · oral · 8 weeksAs given in this study (human).
Source sentences
Summary
Significant increases, with the exception of peak PRL, persisted at 2 and 8 weeks of treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
GH and PRL (peak and area under the curve values) were significantly increased after the initial dose of MK-677.
Summary · context
The study was randomized, double blind, parallel, and placebo controlled.
Summary · context
Twenty-four obese males, aged 18-50 yr, with body mass indexes greater than 30 kg/m2 and waist/hip ratios greater than 0.95, were treated with MK-677 25 mg (n = 12) or placebo (n = 12) daily for 8 weeks.
Report a problemFND-0946754208
09HumanRandomized controlled trialEfficacy outcome
In obese males, increased PRL area under the curve persisted during repeated MK‑677 treatment.
In plain wordsIn obese males, increased prolactin area under the curve persisted during repeated MK‑677 treatment.
Peptide
MK-677 (ibutamoren)
Outcome
IncreasePersistent PRL area under the curve
Study
n = 24
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
25 mg daily · oral · 8 weeksAs given in this study (human).
Source sentences
Summary
Significant increases, with the exception of peak PRL, persisted at 2 and 8 weeks of treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
GH and PRL (peak and area under the curve values) were significantly increased after the initial dose of MK-677.
Summary · context
The study was randomized, double blind, parallel, and placebo controlled.
Summary · context
Twenty-four obese males, aged 18-50 yr, with body mass indexes greater than 30 kg/m2 and waist/hip ratios greater than 0.95, were treated with MK-677 25 mg (n = 12) or placebo (n = 12) daily for 8 weeks.
Report a problemFND-0946754209
10HumanRandomized controlled trialEfficacy outcome
In obese males, the significant peak PRL increase did not persist during repeated MK‑677 treatment.
In plain wordsIn obese males, the significant peak prolactin increase did not persist during repeated MK‑677 treatment.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changePersistent PRL peak
Study
n = 24
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
25 mg daily · oral · 8 weeksAs given in this study (human).
Source sentences
Summary
Significant increases, with the exception of peak PRL, persisted at 2 and 8 weeks of treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
GH and PRL (peak and area under the curve values) were significantly increased after the initial dose of MK-677.
Summary · context
The study was randomized, double blind, parallel, and placebo controlled.
Summary · context
Twenty-four obese males, aged 18-50 yr, with body mass indexes greater than 30 kg/m2 and waist/hip ratios greater than 0.95, were treated with MK-677 25 mg (n = 12) or placebo (n = 12) daily for 8 weeks.
Report a problemFND-0946754210
11HumanRandomized controlled trialEfficacy outcome
In obese males, MK‑677 did not increase serum cortisol compared with placebo.
In plain wordsIn obese males, MK‑677 did not increase serum cortisol compared with placebo.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changeSerum cortisol
Study
n = 24
Comparator
Placebo
Outcome group
Stress hormones · Endocrine and hormones
Studied dose
25 mg daily · oral · 8 weeksAs given in this study (human).
Source sentences
Summary
Serum and urinary concentrations of cortisol were not increased at 2 and 8 weeks (P = NS, vs. placebo).
2 context sentences(design, population, supporting numbers)
Summary · context
The study was randomized, double blind, parallel, and placebo controlled.
Summary · context
Twenty-four obese males, aged 18-50 yr, with body mass indexes greater than 30 kg/m2 and waist/hip ratios greater than 0.95, were treated with MK-677 25 mg (n = 12) or placebo (n = 12) daily for 8 weeks.
Report a problemFND-0946754213
12HumanRandomized controlled trialEfficacy outcome
In obese males, MK‑677 did not increase urinary cortisol compared with placebo.
In plain wordsIn obese males, MK‑677 did not increase urinary cortisol compared with placebo.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changeUrinary cortisol
Study
n = 24
Comparator
Placebo
Outcome group
Stress hormones · Endocrine and hormones
Studied dose
25 mg daily · oral · 8 weeksAs given in this study (human).
Source sentences
Summary
Serum and urinary concentrations of cortisol were not increased at 2 and 8 weeks (P = NS, vs. placebo).
2 context sentences(design, population, supporting numbers)
Summary · context
The study was randomized, double blind, parallel, and placebo controlled.
Summary · context
Twenty-four obese males, aged 18-50 yr, with body mass indexes greater than 30 kg/m2 and waist/hip ratios greater than 0.95, were treated with MK-677 25 mg (n = 12) or placebo (n = 12) daily for 8 weeks.
Report a problemFND-0946754214
13HumanRandomized controlled trialEfficacy outcome
In obese males, MK‑677 increased fat-free mass measured by dual energy x-ray absorptiometry.
In plain wordsIn obese males, MK‑677 increased fat-free mass measured by absorptiometry.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseFat-free mass by absorptiometry
Study
n = 24
Outcome group
Body composition · Metabolic and weight
Studied dose
25 mg daily · oral · 8 weeksAs given in this study (human).
Measurements
P value for fat-free mass increase by dual energy x-ray absorptiometry
< 0.01 unitless
MK-677 treatment group; comparison not stated
Source sentences
Summary
Fat-free mass increased significantly in the MK-677 treatment group when determined with dual energy x-ray absorptiometry (P < 0.01) or using a four-compartment model (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
The study was randomized, double blind, parallel, and placebo controlled.
Summary · context
Twenty-four obese males, aged 18-50 yr, with body mass indexes greater than 30 kg/m2 and waist/hip ratios greater than 0.95, were treated with MK-677 25 mg (n = 12) or placebo (n = 12) daily for 8 weeks.
Report a problemFND-0946754215
14HumanRandomized controlled trialEfficacy outcome
In obese males, MK‑677 increased fat-free mass measured by a four-compartment model.
In plain wordsIn obese males, MK‑677 increased fat-free mass measured by a four-compartment model.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseFat-free mass by four-compartment model
Study
n = 24
Outcome group
Body composition · Metabolic and weight
Studied dose
25 mg daily · oral · 8 weeksAs given in this study (human).
Measurements
P value for fat-free mass increase by four-compartment model
< 0.05 unitless
MK-677 treatment group; comparison not stated
Source sentences
Summary
Fat-free mass increased significantly in the MK-677 treatment group when determined with dual energy x-ray absorptiometry (P < 0.01) or using a four-compartment model (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
The study was randomized, double blind, parallel, and placebo controlled.
Summary · context
Twenty-four obese males, aged 18-50 yr, with body mass indexes greater than 30 kg/m2 and waist/hip ratios greater than 0.95, were treated with MK-677 25 mg (n = 12) or placebo (n = 12) daily for 8 weeks.
Report a problemFND-0946754216
15HumanRandomized controlled trialEfficacy outcome
In obese males, MK‑677 did not significantly change total fat.
In plain wordsIn obese males, MK‑677 did not significantly change total fat.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changeTotal fat
Study
n = 24
Outcome group
Body composition · Metabolic and weight
Studied dose
25 mg daily · oral · 8 weeksAs given in this study (human).
Source sentences
Summary
Total and visceral fat were not significantly changed with active therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
The study was randomized, double blind, parallel, and placebo controlled.
Summary · context
Twenty-four obese males, aged 18-50 yr, with body mass indexes greater than 30 kg/m2 and waist/hip ratios greater than 0.95, were treated with MK-677 25 mg (n = 12) or placebo (n = 12) daily for 8 weeks.
Report a problemFND-0946754217
16HumanRandomized controlled trialEfficacy outcome
In obese males, MK‑677 did not significantly change visceral fat.
In plain wordsIn obese males, MK‑677 did not significantly change visceral fat.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changeVisceral fat
Study
n = 24
Outcome group
Body composition · Metabolic and weight
Studied dose
25 mg daily · oral · 8 weeksAs given in this study (human).
Source sentences
Summary
Total and visceral fat were not significantly changed with active therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
The study was randomized, double blind, parallel, and placebo controlled.
Summary · context
Twenty-four obese males, aged 18-50 yr, with body mass indexes greater than 30 kg/m2 and waist/hip ratios greater than 0.95, were treated with MK-677 25 mg (n = 12) or placebo (n = 12) daily for 8 weeks.
Report a problemFND-0946754218
17HumanRandomized controlled trialEfficacy outcome
In obese males, MK‑677 significantly increased basal metabolic rate at 2 weeks.
In plain wordsIn obese males, MK‑677 significantly increased basal metabolic rate at 2 weeks.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseBasal metabolic rate at 2 weeks
Study
n = 24
Outcome group
Energy expenditure and thermogenesis · Metabolic and weight
Studied dose
25 mg daily · oral · 2 weeksAs given in this study (human).
Measurements
P value for basal metabolic rate increase at 2 weeks
0.01 unitless
MK-677 treatment, 2 weeks; comparison not stated
Source sentences
Summary
The basal metabolic rate was significantly increased at 2 weeks of MK-677 treatment (P = 0.01) but not at 8 weeks (P = 0.1).
2 context sentences(design, population, supporting numbers)
Summary · context
The study was randomized, double blind, parallel, and placebo controlled.
Summary · context
Twenty-four obese males, aged 18-50 yr, with body mass indexes greater than 30 kg/m2 and waist/hip ratios greater than 0.95, were treated with MK-677 25 mg (n = 12) or placebo (n = 12) daily for 8 weeks.
Report a problemFND-0946754219
18HumanRandomized controlled trialEfficacy outcome
In obese males, MK‑677 did not significantly increase basal metabolic rate at 8 weeks.
In plain wordsIn obese males, MK‑677 did not significantly increase basal metabolic rate at 8 weeks.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changeBasal metabolic rate at 8 weeks
Study
n = 24
Outcome group
Energy expenditure and thermogenesis · Metabolic and weight
Studied dose
25 mg daily · oral · 8 weeksAs given in this study (human).
Measurements
P value for basal metabolic rate increase at 8 weeks
0.1 unitless
MK-677 treatment, 8 weeks; comparison not stated
Source sentences
Summary
The basal metabolic rate was significantly increased at 2 weeks of MK-677 treatment (P = 0.01) but not at 8 weeks (P = 0.1).
2 context sentences(design, population, supporting numbers)
Summary · context
The study was randomized, double blind, parallel, and placebo controlled.
Summary · context
Twenty-four obese males, aged 18-50 yr, with body mass indexes greater than 30 kg/m2 and waist/hip ratios greater than 0.95, were treated with MK-677 25 mg (n = 12) or placebo (n = 12) daily for 8 weeks.
Report a problemFND-0946754220
19HumanRandomized controlled trialEfficacy outcome
In obese males, fasting glucose was unchanged during MK‑677 treatment.
In plain wordsIn obese males, fasting glucose was unchanged during MK‑677 treatment.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changeFasting glucose
Study
n = 24
Outcome group
Glycemic control · Metabolic and weight
Studied dose
25 mg daily · oral · 8 weeksAs given in this study (human).
Source sentences
Summary
Fasting concentrations of glucose and insulin were unchanged, whereas an oral glucose tolerance test showed impairment of glucose homeostasis at 2 and 8 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
The study was randomized, double blind, parallel, and placebo controlled.
Summary · context
Twenty-four obese males, aged 18-50 yr, with body mass indexes greater than 30 kg/m2 and waist/hip ratios greater than 0.95, were treated with MK-677 25 mg (n = 12) or placebo (n = 12) daily for 8 weeks.
Report a problemFND-0946754221
20HumanRandomized controlled trialEfficacy outcome
In obese males, fasting insulin was unchanged during MK‑677 treatment.
In plain wordsIn obese males, fasting insulin was unchanged during MK‑677 treatment.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changeFasting insulin
Study
n = 24
Outcome group
Glycemic control · Metabolic and weight
Studied dose
25 mg daily · oral · 8 weeksAs given in this study (human).
Source sentences
Summary
Fasting concentrations of glucose and insulin were unchanged, whereas an oral glucose tolerance test showed impairment of glucose homeostasis at 2 and 8 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
The study was randomized, double blind, parallel, and placebo controlled.
Summary · context
Twenty-four obese males, aged 18-50 yr, with body mass indexes greater than 30 kg/m2 and waist/hip ratios greater than 0.95, were treated with MK-677 25 mg (n = 12) or placebo (n = 12) daily for 8 weeks.
Report a problemFND-0946754222
21HumanRandomized controlled trialEfficacy outcome
In obese males, MK‑677 impaired glucose homeostasis during oral glucose tolerance testing.
In plain wordsIn obese males, MK‑677 impaired glucose control during oral glucose tolerance testing.
Peptide
MK-677 (ibutamoren)
Outcome
DecreaseOral glucose tolerance
Study
n = 24
Outcome group
Glycemic control · Metabolic and weight
Studied dose
25 mg daily · oral · 8 weeksAs given in this study (human).
Source sentences
Summary
Fasting concentrations of glucose and insulin were unchanged, whereas an oral glucose tolerance test showed impairment of glucose homeostasis at 2 and 8 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
The study was randomized, double blind, parallel, and placebo controlled.
Summary · context
Twenty-four obese males, aged 18-50 yr, with body mass indexes greater than 30 kg/m2 and waist/hip ratios greater than 0.95, were treated with MK-677 25 mg (n = 12) or placebo (n = 12) daily for 8 weeks.
Report a problemFND-0946754223
22HumanRandomized controlled trialEfficacy outcome
In obese males, GH increases were smaller after multiple MK‑677 doses than after the initial dose.
In plain wordsIn obese males, growth hormone increases were smaller after multiple MK‑677 doses than after the initial dose.
Peptide
MK-677 (ibutamoren)
Outcome
DecreaseGH response attenuation
Study
n = 12
Comparator
Initial MK-677 dose
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
25 mg daily · oral · 8 weeksAs given in this study (human).
Source sentences
Summary
The increases in GH and PRL after the initial dose were significantly greater than the increase seen after multiple doses.
2 context sentences(design, population, supporting numbers)
Summary · context
The study was randomized, double blind, parallel, and placebo controlled.
Summary · context
Twenty-four obese males, aged 18-50 yr, with body mass indexes greater than 30 kg/m2 and waist/hip ratios greater than 0.95, were treated with MK-677 25 mg (n = 12) or placebo (n = 12) daily for 8 weeks.
Report a problemFND-0946754211
23HumanRandomized controlled trialEfficacy outcome
In obese males, PRL increases were smaller after multiple MK‑677 doses than after the initial dose.
In plain wordsIn obese males, prolactin increases were smaller after multiple MK‑677 doses than after the initial dose.
Peptide
MK-677 (ibutamoren)
Outcome
DecreasePRL response attenuation
Study
n = 12
Comparator
Initial MK-677 dose
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
25 mg daily · oral · 8 weeksAs given in this study (human).
Source sentences
Summary
The increases in GH and PRL after the initial dose were significantly greater than the increase seen after multiple doses.
2 context sentences(design, population, supporting numbers)
Summary · context
The study was randomized, double blind, parallel, and placebo controlled.
Summary · context
Twenty-four obese males, aged 18-50 yr, with body mass indexes greater than 30 kg/m2 and waist/hip ratios greater than 0.95, were treated with MK-677 25 mg (n = 12) or placebo (n = 12) daily for 8 weeks.
Report a problemFND-0946754212

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.